Physician profile
Ambreen A Mardhani
NPI 1043657521
$524.47
in general payments reported to CMS, 2019-2025
14 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.10 · 2022: $12.66 · 2023: $69.47 · 2024: $241 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $130.21 | 2024-2025 | |
| Exact Sciences Corporation | $61.16 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $60.87 | 2024-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $55.75 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $42.75 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.85 | 2023-2024 | Ofev |
| Lilly USA, LLC | $29.30 | 2024 | Mounjaro, Zepbound |
| Abbvie INC. | $28.72 | 2023-2025 | |
| Abbott Laboratories | $18.01 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $17.74 | 2024 | Repatha, Otezla |
| Medtronic USA, INC. | $17.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.66 | 2022 | |
| Dynavax Technologies Corporation | $10.74 | 2024 | Heplisav-B |
| Sumitomo Pharma America, INC. | $8.34 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambreen Mardhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.